Tech Transfer Roundup: Amicus Adds Gene Therapy Technology In UPenn Partnership
Executive Summary
Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.
You may also be interested in...
Amicus Spins Out Rare Disease Gene Therapy Pipeline, Raises $200m
While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.
Amicus Makes Its Gene Therapy Move, Focusing On CNS Lysosomal Storage Disorders
The rare disease specialist gained 10 gene therapy programs with the acquisition of Celenex, including two in clinical-stage development for Batten disease, in exchange for $100m up front. President Bradley Campbell talked to Scrip about the process that led to the deal and next steps for development.
Akero Shows FGF21/GLP-1 Combo’s Potential In NASH And Type 2 Diabetes
Phase IIb data show that Akero’s efruxifermin on top of GLP-1 therapy is relatively safe and offers liver fat reductions and fibrosis improvements in NASH patients with type 2 diabetes.